Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modelling approaches to dose estimation in children.

Trevor N Johnson1

  • 1Simcyp Ltd, Blades Enterprise Centre, John Street, Sheffield S2 4SU, UK. t.johnson@simcyp.com

British Journal of Clinical Pharmacology
|June 14, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of Thermal Radiofrequency Ablation of Lumbar Medial Branches as Treatment for Chronic Low Back Pain.

Pain and therapy·2026
Same author

The rational use of PBPK to assess the changing DDI liability in pediatrics: Model qualification and the move towards best practice.

Drug metabolism and pharmacokinetics·2026
Same author

Development, Verification, and Application of a Chinese Pediatric Physiologically Based Pharmacokinetic Model: Emphasis on CYP Metabolism and Renal Elimination.

The AAPS journal·2025
Same author

Outcomes of Cooled Radiofrequency Ablation of Lumbar Nerves as Treatment for Chronic Low Back Pain.

Pain and therapy·2025
Same author

Randomised, placebo-controlled, double-blinded, four-way crossover trial to demonstrate the comparative pharmacodynamic equivalence of a non-invasive diagnostic test for adrenal insufficiency in a healthy population: the STARLIT-2 study protocol.

BMJ open·2025
Same author

A guide to developing population files for physiologically-based pharmacokinetic modeling in the Simcyp Simulator.

CPT: pharmacometrics & systems pharmacology·2024
Same journal

N-acetylcysteine for non-paracetamol-induced acute liver failure in children: A systematic review and meta-analysis.

British journal of clinical pharmacology·2026
Same journal

Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis.

British journal of clinical pharmacology·2026
Same journal

Modelling immune gene expression profiles as pharmacodynamic endpoints of antileishmanial treatment.

British journal of clinical pharmacology·2026
Same journal

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

British journal of clinical pharmacology·2026
Same journal

Relationship between continuous infusion meropenem PK/PD target attainment and C-reactive protein dynamics in onco-haematologic patients with febrile neutropenia.

British journal of clinical pharmacology·2026
Same journal

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology·2026
See all related articles

Pediatric drug dosing requires careful consideration as children are not small adults. Extrapolation methods provide initial pediatric dose estimates, but pharmacokinetic (PK) studies are essential for safe and effective dosing in all pediatric age groups.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Drug Development

Background:

  • Most drugs are developed for adults, with dosages optimized for efficacy and safety in this population.
  • Children's unique physiology necessitates distinct drug selection and dosage strategies, as they are not simply smaller versions of adults.
  • Pediatric populations exhibit unique susceptibilities to adverse drug reactions.

Purpose of the Study:

  • To highlight the challenges in pediatric drug dosing.
  • To emphasize the need for specialized approaches in determining pediatric drug dosages.
  • To underscore the importance of pharmacokinetic and pharmacodynamic studies in pediatric drug development.

Main Methods:

  • Extrapolation approaches for initial pediatric dose estimation.

Related Experiment Videos

  • Pharmacokinetic (PK) studies.
  • Pharmacokinetic-pharmacodynamic (PK-PD) studies.

    • Main Results:

    • Initial dose estimations in pediatrics can be derived through extrapolation.
    • Extrapolation alone is insufficient for establishing optimal pediatric drug doses.
    • Well-conducted PK-PD or PK studies are crucial for determining appropriate pediatric dosages.

    Conclusions:

    • Pediatric drug dosing requires a specialized approach, acknowledging that children are not small adults.
    • Extrapolation methods serve as a starting point for pediatric dose selection.
    • Robust PK and PK-PD studies are indispensable for ensuring the safety and efficacy of medications in neonates, infants, children, and adolescents.